Previous proteomic and transcriptional analyses of multiple sclerosis lesions 1-3 revealed modulation of the renin-angiotensin and the opposing kallikrein-kinin pathways. Here we identify kinin receptor B1 (Bdkrb1) as a specific modulator of immune cell entry into the central nervous system (CNS). We demonstrate that the Bdkrb1 agonist R838 (Sar-[D-Phe]desArg 9 -bradykinin) markedly decreases the clinical symptoms of experimental autoimmune encephalomyelitis (EAE) in SJL mice [4] [5] [6] , whereas the Bdkrb1 antagonist R715 (Ac-Lys-[DbNal 7 , Ile 8 ]des-Arg 9 -bradykinin) resulted in earlier onset and greater severity of the disease. Bdkrb1-deficient (Bdkrb1 À/À ) C57BL/6 mice 7 immunized with a myelin oligodendrocyte glycoprotein fragment, MOG , showed more severe disease with enhanced CNS-immune cell infiltration. The same held true for mixed bone marrow-chimeric mice reconstituted with Bdkrb1 À/À T lymphocytes, which showed enhanced T helper type 17 (T H 17) cell invasion into the CNS. Pharmacological modulation of Bdkrb1 revealed that in vitro migration of human T H 17 lymphocytes across blood-brain barrier endothelium is regulated by this receptor. Taken together, these results suggest that the kallikrein-kinin system is involved in the regulation of CNS inflammation, limiting encephalitogenic T lymphocyte infiltration into the CNS, and provide evidence that Bdkrb1 could be a new target for the treatment of chronic inflammatory diseases such as multiple sclerosis.
Three independent mRNA and protein screens performed on inflammatory lesions of the central nervous system (CNS) (ref. 1, 2) and on blood-brain barrier (BBB) membrane microdomains 3 revealed unexpected changes in both the renin-angiotensin and the kallikreinkinin systems (KKS), two pathways that are known mainly for their role in blood pressure regulation and are proposed to counterbalance each other 8 . For example, in a large-scale analysis of mRNA transcripts from multiple sclerosis lesions, prokallikrein KLKB1 was more abundant in samples from all lesion types relative to control brain samples, whereas the kallikrein inhibitor kallistatin was less abundant 1 . In a proteomic study, neurolysin, which hydrolyzes bradykinin, was present in chronic active and chronic plaques, whereas lysosomal carboxypeptidase, which cleaves angiotensins as well as des-Arg 9 -bradykinin, was found only in active plaques 2 . Kinins belong to a family of bioactive octa-to decapeptides generated from kininogens in a stepwise cleavage process 9 . Their biological activities are mediated via two pharmacologically distinct G protein-coupled receptors: kinin receptor B1 (Bdkrb1), which under physiological conditions is not found in immune cells, and the ubiquitously expressed kinin receptor B2 (Bdkrb2). In the mouse EAE model of multiple sclerosis, we found upregulation of Bdkrb1, bradykinin, des-Arg 9 -bradykinin, kallikrein-1 and kallikrein-6 as well as low-molecular-weight kininogens (KNGL) in CNS tissue and the cerebrospinal fluid ( Supplementary Fig. 1 ). Because kallikreins cleave the precursor kininogens to bradykinin, which mediates its effect primarily via Bdkrb2, and subsequent proteases generate des-Arg 9 -bradykinin, acting via Bdkrb1, we assumed that the kallikrein-kinin system may contribute to chronic autoimmune neuroinflammation. Bdkrb1 expression has been found not only on brain endothelial cells 10 but also on T lymphocytes from individuals with multiple sclerosis 11, 12 and, as shown here, on parenchymal CD3 + T cells within perivascular lesions (Fig. 1a) .
In light of the known involvement of such T cells in the initiation of a myelin-specific immune attack, we induced EAE via adoptive transfer of activated proteolipid protein (PLP) 139-151 -specific lymphocytes into naive SJL/J mice 5, 6 . We treated recipients with the Bdkrb1 agonist R838 (1 mg kg -1 ), the Bdkrb1 antagonist R715 (1 mg kg -1 ), or with vehicle, from day 0 to day 10 after transfer. Activation of Bdkrb1 resulted in a significantly lower maximum clinical disease severity and milder clinical deficits than occurred in vehicle-treated mice (P o 0.01), whereas blocking of Bdkrb1 led to accelerated disease onset (P ¼ 0.01; Fig. 1b) . To analyze the potential of Bdkrb1 activation for therapeutic use, we immunized SJL/J mice to produce relapsing-remitting EAE and treated them after disease onset with R838 (1 mg kg -1 ) or vehicle. Bdkrb1 activation resulted in a significantly attenuated clinical disease course (P o 0.05; Fig. 1c) .
To elucidate the role of Bdkrb1 in chronic CNS neuroinflammation, we immunized Bdkrb1-deficient (Bdkrb1 À/À ) C57BL/6 mice 7 or wildtype (WT) C57BL/6 controls with myelin oligodendrocyte glycoprotein (MOG) . Bdkrb1 À/À mice had both a significantly greater maximum clinical disease severity (P o 0.05) and greater clinical deficits (Fig. 1d) . To rule out a possible compensatory role of the constitutively expressed Bdkrb2 in Bdkrb1 À/À mice, we next immunized C57BL/6 mice lacking the genes encoding kinin receptors B1 and B2 (ref. 13) (Bdkrb1 À/À ;Bdkrb2 À/À mice) with MOG . Despite a recently reported potential proinflammatory role of Bdkrb2 (ref. 14) , we found no difference between the EAE disease courses in Bdkrb1 À/À ;Bdkrb2 À/À and Bdkrb1 À/À mice (P 4 0.05), which indicates that Bdkrb1 has a dominant role in influencing the course of the disease (Fig. 1e) .
Histological examination at day 23 after immunization ( Fig. 1d ) revealed large inflammatory infiltrates, including an elevated number of activated microglia and macrophages throughout the brain stem and spinal cord, in Bdkrb1 À/À mice with EAE as compared to control WT mice with EAE (Fig. 2a,b) . In parallel, the extent of demyelination and axonal damage, the main pathological feature of multiple sclerosis 15 , was greater in the Bdkrb1 À/À mice (Fig. 2c,d) . In contrast to the strong effects of Bdkrb1 on disease severity and histological parameters, however, the myelin-specific T cell response as well as the activation status of T cells in the peripheral immune organs of the Bdkrb1 À/À mice were unaltered as compared to those of the controls (Fig. 2e-h) . Moreover, the proportion of FoxP3 + CD25 + regulatory T cells 16 within the CD4 + lymphocyte population from draining lymph nodes was similar in the Bdkrb1 À/À mice with EAE (13.1% ± 1.2) and the WT control mice with EAE (11.9% ± 0.8.; P 4 0.05).
To further dissect which cell type is influenced by Bdkrb1 signaling during the disease, we generated bone marrow-chimeric mice 17 by injecting C57BL/6-CD45.2 bone marrow into lethally irradiated C57BL/6-CD45.1 recipient mice. In the first group, we reconstituted lethally irradiated congenic C57BL/6-CD45.1 mice with a mixed bone marrow consisting of a 5:1 ratio of T cell receptor (TCR) b-chain (Tcrb À/À )-deficient and Bdkrb1-deficient bone marrow donors 18, 19 . The resulting Bdkrb1 À/À Tcrb À/À -WT mixed-bone-marrow chimera lacked Bdkrb1 on T cells. In a second group, we gave irradiated C57BL/6-CD45.1 mice Bdkrb1 À/À bone marrow only, in which all reconstituted immune cells were devoid of Bdkrb1 (Bdkrb1 À/À -WT). To rule out a bias through irradiation and BM reconstitution, we gave a third group of mice a 5:1 ratio of Tcrb À/À and C57BL/6 (WT) bone marrow (WT Tcrb À/À -WT). Two months after bone marrow grafting, we assessed reconstitution by FACS analysis of peripheral blood and PCR analysis of MACS-sorted CD3 + and CD11b + cells ( Supplementary Fig. 2a) . Immunization with MOG 35-55 to produce active EAE revealed an earlier onset and markedly greater clinical deficits in Bdkrb1 À/À -WT bone marrow chimeras as compared to WT Tcrb À/À -WT EAE controls (P o 0.05; Fig. 3a) . This pattern was similar to the EAE disease courses in germline Bdkrb1 À/À mice as compared to WT C57BL/6 controls (Fig. 1d) . We found that mean EAE disease scores in Bdkrb1 À/À ( Supplementary Fig. 2b ), indicating that antigen-specific immune responses against the encephalitogenic peptide were not compromised by kinin receptor B1 deficiency (Fig. 3a) . Next, we reconstituted Bdkrb1-deficient mice with a mix of TCR-b-chain-deficient and C57BL/6-CD45.1 bone marrow (WT Tcrb À/À -Bdkrb1 À/À ). After immunization with MOG 35-55 , EAE course in these mice was compared to that in Bdkrb1 À/À -WT as well as Bdkrb1 À/À -Bdkrb1 À/À mice (Fig. 3b) . Disease courses were comparable in mice deficient for Bdkrb1 in the immune system; however, the disease was ameliorated in the mice reconstituted with WT T cells (P o 0.05). These data demonstrate that the protective effect of Bdkrb1 is mediated by its expression on T cells and exclude a possible contribution of Bdkrb1 expression in the CNS.
We therefore investigated whether Bdkrb1 would modulate CNS inflammation by affecting the migration of encephalitogenic T cells across the BBB (Fig. 3) . To directly compare and quantify the homing capacity to the CNS in vivo, we reconstituted C57BL/6 mice with mixed bone marrow consisting of a 1:1 ratio of WT (C57BL/6-CD45.1) and Bdkrb1 À/À (C57BL/6-CD45.2) bone marrow. Infiltration of Bdkrb1 À/À T cells into the CNS, normalized to the reconstitution rate, was significantly higher than infiltration of WT T cells at disease peak (Fig. 3c) . Moreover, we found more CD4 + T cells in the CNS when encephalitogenic Bdkrb1 À/À T cells, as opposed to WT T cells, were transferred to Rag1 À/À recipients (Fig. 4a) . In line with this, we observed an EAE incidence of 75% when transferring Bdkrb1 À/À T cells but only of 33% with WT T cells (Supplementary Table 1) . Using an in vitro Transwell assay, we found that PLP 139-151 -and MOG 35-55 -specific CD4 + T cells isolated from immunized SJL/J and Bdkrb1 À/À mice were attracted to migrate through a monolayer of transformed mouse brain-derived endothelial cells (ref. 20 ) in a CXCL12 gradient-dependent manner. Although engagement of Bdkrb1 by R838 considerably reduced the number of migrated T cells, the additional application of the Bdkrb1 antagonist R715 restored migration. By contrast, the migration of Bdkrb1 À/À cells was not altered (Fig. 3d) . In PLP-specific T cells treated with R838, we did not find any alterations in adhesion molecule expression (LFA-1, VLA-4, ICAM, ALCAM, VCAM-1 and CD6; see Supplementary Table 2 for oligonucleotide primers). In contrast, we observed a markedly decreased polymerization of F-actin upon short-term Bdkrb1 activation (Fig. 3e) . Moreover, in CD4 + T cells the activity of the small GTPase RhoA-which controls T cell migration 21 -was also downregulated (Fig. 3f) . Thus, activation of the G protein-coupled kinin receptor B1 directly regulates signaling events that are important for T lymphocyte motility.
Bdkrb1 seems to affect CNS inflammation and control the migration of proinflammatory T cells across the BBB into the 
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NATURE MEDICINE VOLUME 15 [ NUMBER 7 [ JULY 2009 CNS. Indeed, analysis of immune cells recovered from the CNS of mice with EAE revealed that after adoptive transfer of Bdkrb1 À/À into Rag1 À/À mice, the proportion of CD4 + T cells within the CNS-infiltrating immune cells was significantly higher than that in mice that had received only WT T cells (Fig. 4a) . Notably, within the same CNS-derived CD4 + T cell population, the proportion of IL-17 + CD4 + T lymphocytes-regarded as crucial for the initiation and maintenance of autoimmune neuroinflammation 22 -was greater in Bdkrb1 À/À mice with EAE, whereas the proportion of IFN-g-producing T cells was comparable, relative to those in WT control mice with EAE (Fig. 4b,c) . Supplementary Fig. 3 ), demonstrating that Bdkrb1 has no impact on the generation of antigen-specific T H 17 lymphocytes. However, in the CNS of Bdkrb1 À/À Tcrb À/À -WT mice with EAE, in which the T cell population was deficient for Bdkrb1, the proportion of IL-17 + subsets was markedly greater than among cells isolated from WT Tcrb À/À -WT mice with EAE. We did not observe any differences in the proportions of either IFN-g-producing T cells or FoxP3 + CD25 + T cells (Fig. 4d-f) .
Using in vitro migration assays, we next investigated the effect of R838 and R715 on the migration of mouse and human memory CD45RO + T H 17 and T H 1 lymphocytes ( Supplementary Fig. 4 ) 25 . Addition of R838 resulted in a significant reduction in the migration of T H 17, but not T H 1, lymphocytes toward a CXCL12 chemokine gradient for mouse T cells and across human brain-derived microvascular endothelial cells for human T cells ( Fig. 4g and Supplementary Fig. 5 ). These data also point to the important contribution of kinin receptor B1 as a modulator of the recruitment of pathogenic lymphocytes to the CNS. To find a possible explanation for the specific effect on T H 17 cells, we analyzed the expression of Bdkrb1 in T H 1 and T H 17 cells generated from different transgenic mouse strains (2d2, OT-2) as well as from human sources. In fact, T H 17 cells showed a markedly higher expression of Bdkrb1 than did T H 1 cells (Fig. 4h and Supplementary Fig. 5 ).
To finally demonstrate an influence of Bdkrb1 signaling on the migration pattern of T H 17 cells, we treated fluorescence-labeled mouse T H 17 lymphocytes with the Bdkrb1 modulators or vehicle before allowing them to infiltrate into syngeneic hippocampal slice cultures 26 . Two-photon microscopy analysis revealed a lower mean velocity ( Supplementary Fig. 6 ) and reduced infiltrative behavior upon Bdkrb1 activation (Fig. 4i,j and Supplementary Movies 1-3) .
Altogether, our data suggest the existence of a hitherto unknown endogenous control mechanism that limits harmful antigen-specific immune responses targeting the CNS, and they define the kinin receptor B1 as an important regulator for the homing of encephalitogenic T lymphocytes into the CNS. Progress toward the development of new therapies for chronic inflammation is urgently needed 27, 28 . In principle, activation of the body's innate control mechanisms, such as those identified here, may offer certain advantages over previous strategies aimed at selectively blocking structures involved in inflammatory CNS infiltration 29 . Newly developed kinin receptor agonists with improved pharmacological properties in regard to half-life and receptor specificity may provide promising new tools for the therapeutic manipulation of the kallikrein-kinin system in immune-mediated diseases. For the related renin-angiotensin system, blockade by an angiotensin-converting enzyme inhibitor suppresses inflammation in the CNS (L.S., personal communication). Thus, modification of major systems known for their cardiovascular roles may open the way toward new therapies for chronic inflammatory diseases such as multiple sclerosis. 
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